Christopher Cutie from J and J joins the show to discuss the SUNRISE bladder program. Drs. Maite Bourlon, Elena Castro and Cristina Suarez cover the UC topics discussed on day 1 of Uromigos Live 2024. Listen to the podcast format of the peri-operative therapy in bladder cancer panel from Uromigos Live 2024. Listen to the podcast format of the panel on on emerging ADC data in bladder cancer from Uromigos Live 2024. Tom and Brian finish discussing bladder and kidney cancer highlights from ESMO 2024. Fresh off the Presidential session address, Tom discusses his data with Petros commenting. Matt Galsky describes his ESMO 2024 abstract of disitimab vedotin + pembrolizumab in bladder cancer. Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon discuss recent ESMO guideline changes on GU cancers. Dr. Jonathan Rosenberg discusses the treatment-related side effects of EV/pembro for bladder cancer. Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon host the first Spanish-language ASCO episode for The Uromigos. Drs. Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden get a chance to win The Uromigos Cup. Drs. Viktor Grünwald, Boris Hadaschik and Gunhild Von Amsberg answer trivia for the Uromigos Cup qualifying round. Dr. Aditya Bagrodia discusses new drugs and studies for NMIBC that were presented at this year's AUA meeting. Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup. Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup. Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting. Tom and Brian are joined by David Penson to discuss upcoming presentations to look forward to at AUA. Alison Birtle gives an update on the POUT trial on the use of adjuvant chemotherapy after nephroureterectomy for UTUC. Dr. Galsky describes the OS signal data from CheckMate-274 on adjuvant nivolumab for muscle-invasive bladder cancer. Dr. Matt Galsky, Brian, and Tom discuss the IMvigor011 trial data that was presented at EAU 2024.